Heltra: Explore Life – Discover More – Live Better

Stopping weight-loss drugs may raise risk of stroke or heart attack

Weight-loss drugs help people shed pounds, protecting them from strokes and heart attacks.

But many people gain weight again after stopping taking GLP-1 receptor agonists (GLP-1-RA).

For type 2 diabetes patients, the risk of serious cardiovascular events and death increases significantly once they stop treatment, according to a study published in The Lancet Regional Health Europe.

Some 80,000 people with type 2 diabetes took part in the study carried out by an international research team in Italy. None of the patients had cardiovascular disease and all had started treatment with a GLP-1 RA.

Advertisement

Advertisement

However, 60% subsequently discontinued the treatment. From both groups, the scientists chose nearly 29,000 people each who were broadly comparable. The average age was just under 65 years.

Continuous treatment required for maximum benefit

In the observational study, discontinuing the medication was associated with a doubling of the likelihood of a heart attack, stroke or cardiovascular-related death over the next 3 to 4 years.

Overall mortality in this group was a dramatic 4.8 times higher, according to the study led by Antonio Ceriello from the Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) hospital in Milan, Italy.

Advertisement

Advertisement

It was striking that risk factors such as weight or blood glucose levels had not deteriorated to such an extent as to account for this significantly increased risk on their own.

“These results suggest that continuous treatment may be necessary to achieve maximum benefit in terms of cardiovascular events and mortality,” the team says.

“On the other hand, due to our study design, we were unable to determine the relative risk of starting and subsequently discontinuing GLP-1 RA therapy compared with not using such medicines.”

In general, it is difficult to draw causal links based on the study data, the authors say.

Advertisement

Advertisement

It is possible that discontinuing the medication could already be an indication of a higher underlying risk – and not necessarily a direct cause, they note.

‘GLP-1 receptor agonists only work as long as you take them’

The result comes no surprise to Jochen Seufert, Head of the Department of Endocrinology and Diabetology at the University Medical Centre Freiburg.

“GLP-1 receptor agonists only work as long as you take them,” says the Vice-President of the German Society for Endocrinology. “After that, the positive effects are lost again.”

The risks identified in the study among people with type 2 diabetes are not automatically transferable to the same extent to patients who take the drugs primarily for weight loss, says Seufert.

Advertisement

Advertisement

Nor does he believe that starting and subsequently stopping the treatment increases the risk of cardiovascular problems any more than not using GLP-1 preparations at all. “There is no evidence to suggest that,” he says.

Robert Wagner, head of the Clinical Trials Centre at the German Diabetes Centre (DDZ), says the study provides “a further warning sign, but no proof that discontinuing GLP-1 medicines itself causes cardiovascular events or deaths”.

“It is not possible to assess whether the risk actually rises above the original level after discontinuation, as there is no control group not receiving GLP-1 therapy,” says Wagner, a senior doctor at the Department of Endocrinology and Diabetology at Düsseldorf University Hospital.

Furthermore, the study primarily examined older formulations, he notes.

‘Tolerance varies greatly from person to person’

The findings are significant in that a very large number of users discontinue this treatment. Seufert estimates the proportion at 30% to 50% in the first 6 to 12 months.

Advertisement

Advertisement

That is often due to the gastrointestinal side effects which include constipation, nausea and vomiting.

“Tolerance varies greatly from person to person,” Seufert says. This is precisely why an experienced specialist – ideally an endocrinologist or diabetologist – should monitor your treatment on an ongoing basis and adjust the dose gradually over the course of treatment.

“An effective and well-tolerated GLP-1 therapy should be planned for the long term and reviewed regularly,” Wagner says. “In the event of an inadequate response or side effects, a targeted adjustment and a plan for further treatment are required.”

Source link

ADVERTISEMENT